Evotec (EVO) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Evotec (EVO) over the past year, gaining 66.2% versus a loss of 58.9%. Over five years, TKNO leads with a -62.3% price change compared with -92.9% for EVO. Evotec is the larger company by market cap ($572.2 million vs $467.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | TKNO |
|---|---|---|
| Share price | $1.61 | $8.71 |
| Market cap | $572.18M | $467.62M |
| 1-day change | -1.23% | -0.46% |
| YTD return | -47.73% | +129.21% |
| 1-year return | -58.93% | +66.22% |
| 5-year return | -92.87% | -62.29% |
| EPS (TTM) | $-0.64 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.27 | $9.48 |
| 52-week low | $1.50 | $1.91 |
| Distance from 52-week high | -62.30% | -8.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +158.39% | +3.33% |
| Average volume | 104.15K | 230.41K |
| Shares outstanding | 355.39M | 53.69M |
| Employees | 4,461 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TKNO has outperformed EVO by 125.1 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
EVO vs TKNO FAQ
Which is bigger, Evotec or Alpha Teknova?
Evotec (EVO) is larger, with a market capitalization of $572.18M compared with $467.62M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, EVO or TKNO?
TKNO returned +66.22% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Alpha Teknova in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Evotec and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Alpha Teknova.